Powered by HealthTechMovers.com
We added 2 stocks to our Healthcare & Biotech Stock Watchlist today because they are receiving Bullish Sentiment from investors and financial bloggers.
In addition, they are generating positive media buzz and/or have insider trading signals which came to our attention. This list below is subject to change on a daily basis, so please be sure you subscribe to our email newsletter.
ImmunoGen, IMGN
Summary: ImmunoGen Inc is a development-stage biotechnology company focused on the development of targeted cancer therapeutics using its proprietary antibody-drug conjugate technology. ImmunoGen's ADC technology is used in three development-stage candidates in its own pipeline, Roche's marketed product, Kadcyla and in development programs of its partners Bayer, Biotest, CytomX, Novartis, Sanofi, Roche, Takeda, Debiopharm & Jazz Pharmaceuticals.'Among ImmunoGen's wholly owned candidates, mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha, is being developed as a single-agent therapy for platinum-resistant ovarian cancer and in combination regimens for both platinum-resistant and platinum-sensitive disease. The candidate is also being developed in combination with other cancer drugs in a mid-stage study.'Pivekimab sunirine is currently under evaluation in early- to mid-stage studies for treatment of patients with acute myeloid leukemia & other CD123-positive hematological malignancies.
- Last Price: $15.98
- Price Change: -$0.18, -1.11%
- Yearly Gain: 218.11%
- Market Cap: $4.28B
- P/E Ratio: -53.938
Here are 3rd party ratings for IMGN:
- TipRanks.com: Moderate Buy
- TradingView.com:
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Buy, Top 26% (65 out of 251)
What is the sentiment on the street regarding ImmunoGen ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: Medium
- Insider Signal: Neutral
- Investor Sentiment: Very Positive
- Hedge Fund signal: Very Positive
If you are interested in IMGN or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on IMGN before you decide to make any investment.
Click here for chart >>
Rani Therapeutics Holdings, RANI
Summary: Rani Therapeutics Holdings Inc. is a clinical stage biotherapeutics company. It focused on advancing technologies to enable the development of orally administered biologics. Rani Therapeutics Holdings Inc. is based in SAN JOSE, Calif.
- Last Price: $2.00
- Price Change: $0.02, 1.01%
- Yearly Gain: -75.31%
- Market Cap: $100.49M
- P/E Ratio: -1.402
Here are 3rd party ratings for RANI:
- TipRanks.com: Strong Buy
- TradingView.com:
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Buy, Top 19% (47 out of 251)
What is the sentiment on the street regarding Rani Therapeutics Holdings ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: Medium
- Insider Signal: Positive
- Investor Sentiment: Positive
- Hedge Fund signal: No Signal
If you are interested in RANI or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on RANI before you decide to make any investment.
Click here for chart >>
Thanks for reading!
